128 related articles for article (PubMed ID: 25104793)
21. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
[TBL] [Abstract][Full Text] [Related]
22. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
23. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.
Beesley AH; Palmer ML; Ford J; Weller RE; Cummings AJ; Freitas JR; Firth MJ; Perera KU; de Klerk NH; Kees UR
Br J Haematol; 2007 Apr; 137(2):109-16. PubMed ID: 17391490
[TBL] [Abstract][Full Text] [Related]
24. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
[TBL] [Abstract][Full Text] [Related]
25. Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs.
Campana D; Manabe A; Evans WE
Leukemia; 1993 Mar; 7(3):482-8. PubMed ID: 7680404
[TBL] [Abstract][Full Text] [Related]
26. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
[TBL] [Abstract][Full Text] [Related]
27. [Effect of glucocorticoid on the expression of Puma in acute lymphoblastic leukemia].
Xu B; Wang BJ; Li AM; Lock R
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):151-4. PubMed ID: 16613713
[TBL] [Abstract][Full Text] [Related]
28. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
Moradi Manesh D; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB
Blood; 2015 Sep; 126(10):1193-202. PubMed ID: 26116659
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Frismantas V; Dobay MP; Rinaldi A; Tchinda J; Dunn SH; Kunz J; Richter-Pechanska P; Marovca B; Pail O; Jenni S; Diaz-Flores E; Chang BH; Brown TJ; Collins RH; Uhrig S; Balasubramanian GP; Bandapalli OR; Higi S; Eugster S; Voegeli P; Delorenzi M; Cario G; Loh ML; Schrappe M; Stanulla M; Kulozik AE; Muckenthaler MU; Saha V; Irving JA; Meisel R; Radimerski T; Von Stackelberg A; Eckert C; Tyner JW; Horvath P; Bornhauser BC; Bourquin JP
Blood; 2017 Mar; 129(11):e26-e37. PubMed ID: 28122742
[TBL] [Abstract][Full Text] [Related]
30. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses.
Fabricius D; Breckerbohm L; Vollmer A; Queudeville M; Eckhoff SM; Fulda S; Strauss G; Debatin KM; Jahrsdörfer B; Meyer LH
Leukemia; 2011 Jul; 25(7):1111-21. PubMed ID: 21527935
[TBL] [Abstract][Full Text] [Related]
31. High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Oikonomou A; Valsecchi L; Quadri M; Watrin T; Scharov K; Procopio S; Tu JW; Vogt M; Savino AM; Silvestri D; Valsecchi MG; Biondi A; Borkhardt A; Bhatia S; Cazzaniga G; Fazio G; Bardini M; Palmi C
Biochem Pharmacol; 2023 Nov; 217():115809. PubMed ID: 37717691
[TBL] [Abstract][Full Text] [Related]
32. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia.
Bhadri VA; Cowley MJ; Kaplan W; Trahair TN; Lock RB
BMC Genomics; 2011 Nov; 12():565. PubMed ID: 22093874
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Popp-Snijders C; Lomecky M; Van Zantwijk CH; Swinkels LM; Van Wering ER; Pieters R
Med Pediatr Oncol; 1996 Aug; 27(2):114-21. PubMed ID: 8649318
[TBL] [Abstract][Full Text] [Related]
35. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
36. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.
Liem NL; Papa RA; Milross CG; Schmid MA; Tajbakhsh M; Choi S; Ramirez CD; Rice AM; Haber M; Norris MD; MacKenzie KL; Lock RB
Blood; 2004 May; 103(10):3905-14. PubMed ID: 14764536
[TBL] [Abstract][Full Text] [Related]
37. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
38. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
39. Preclinical testing of antileukemic drugs using an in vivo model of systemic disease.
Lock RB; Liem NL; Papa RA
Methods Mol Med; 2005; 111():323-34. PubMed ID: 15911988
[TBL] [Abstract][Full Text] [Related]
40. Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB
Cancer Cell; 2018 Dec; 34(6):906-921.e8. PubMed ID: 30537513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]